Seeking Alpha
22 Aug 2026, 06:57 UTC · 12w ago
Neurocrine Biosciences: 'House Full Of Options'
Impact · against what's priced in
NBIX is positioned as a value play with a strong revenue floor and diversifying growth drivers. The primary catalyst is the gap between current market pricing and DCF valuations, supported by long-term exclusivity for Ingrezza.
- NBIX+0.70
No priced-in read yet
- In context
The combination of Ingrezza's 2038 exclusivity, projected $3.3B peak sales, and the diversification provided by Crenessity and Vykat XR suggests a valuation floor higher than current market levels.
Read from the article alone

Top 1 mover · tap to explore




